|
|
|
|
|
|
|
05.06.25 - 12:48
|
Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo′s Canadian Portfolio (GlobeNewswire EN)
|
|
|
MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America Inc. (“SMPA”) announced today that Knight and SMPA's affiliates have entered into exclusive license and supply agreements to commercialize MYFEMBREE® (relugolix/estradiol/norethindrone acetate), ORGOVYX® (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight will acquire certain mature products (the “Mature Products”, together with MYFEMBREE®, ORGOVYX® and vibegron, the “Products”). For the year ended March 2025, the Products generated C$11.2 million in revenue....
|
|
|
|
|
|
|
|
|
07.05.25 - 13:33
|
Knight Therapeutics Announces Relaunch of ONICIT® in Brazil and Mexico (GlobeNewswire EN)
|
|
|
MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that has assumed full commercial activities and is relaunching ONICIT® IV (palonosetron) in Brazil and Mexico, through its affiliates in those countries (United Medical Ltd. and Grupo Biotoscana de Especialidad S.A. de C.V., respectively)....
|
|
|
01.05.25 - 13:33
|
Notice of Knight Therapeutics′ First Quarter 2025 Results Conference Call (GlobeNewswire EN)
|
|
|
MONTREAL, May 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2025 financial results on Thursday, May 8, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call....
|
|
|
29.04.25 - 22:33
|
Knight to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire EN)
|
|
|
MONTREAL, April 29, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 5, 2025, at 2:00 p.m. ET at the Metro Toronto Convention Centre (North Building) in Toronto. A copy of the presentation will be available at www.knighttx.com....
|
|
|
|
|
|
|
|
|
|
|
13.03.25 - 12:33
|
Notice of Knight Therapeutics′ Fourth Quarter and Year End 2024 Results Conference Call (GlobeNewswire EN)
|
|
|
MONTREAL, March 13, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2024 financial results on Thursday, March 20, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call....
|
|
|
|
|
28.01.25 - 22:33
|
Knight Therapeutics and Helsinn Healthcare SA Expand Relationship and Enter into Exclusive License, Distribution, and Supply Agreement for Onicit® (GlobeNewswire EN)
|
|
|
MONTREAL and LUGANO, Switzerland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, and Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, today announced that Knight, through one of its wholly-owned subsidiaries, and Helsinn have expanded their existing relationship and have entered into an exclusive license, distribution and supply agreement (“Agreement”) for ONICIT® IV (palonosetron) in Mexico, Brazil, and other LATAM countries. ONICIT® is marketed under the brand name ALOXI® in Canada....
|
|
|
|
|
12.12.24 - 13:33
|
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico (GlobeNewswire EN)
|
|
|
MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., received regulatory approval from COFEPRIS for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
